Eculizumab cessation in atypical hemolytic uremic syndrome

Blood. 2017 Jul 20;130(3):368-372. doi: 10.1182/blood-2017-02-770214. Epub 2017 May 1.

Abstract

Publisher's Note: There is an Inside Blood Commentary on this article in this issue.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / economics
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Atypical Hemolytic Uremic Syndrome / drug therapy*
  • Atypical Hemolytic Uremic Syndrome / economics
  • Atypical Hemolytic Uremic Syndrome / therapy
  • Drug Administration Schedule
  • Drug Costs
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Recurrence
  • Renal Dialysis / statistics & numerical data
  • Retrospective Studies

Substances

  • Antibodies, Monoclonal, Humanized
  • eculizumab